英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Cowper查看　Cowper　在百度字典中的解释百度英翻中〔查看〕
Cowper查看　Cowper　在Google字典中的解释Google英翻中〔查看〕
Cowper查看　Cowper　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
    Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
  • More about ADSTILADRIN® – Bladder Cancer Advocacy Network
    What is ADSTILADRIN? ADSTILADRIN (nadofaragene firadenovec-vncg) was approved in the United States in 2022 and is fully available for appropriate patients as a treatment that may help people live better lives on their bladder cancer journey ADSTILADRIN is a localized gene therapy designed to help the immune system fight NMIBC directly within the bladder Administered […]
  • Package Insert - ADSTILADRIN
    ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS
  • First Bladder Cancer Patient Dosed with Commercially Available . . .
    ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
  • FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus . . .
    Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) The product represents the first approved adenoviral vector-based gene therapy and
  • Adstiladrin (Nadofaragene Firadenovec-Vncg) for bladder cancer
    Adstiladrin is also called nadofaragene firadenovec-vncg Adstiladrin is a gene therapy that uses a non-replicating adenoviral vector (a modified virus that cannot multiply) to deliver a gene to bladder cells This gene makes a protein called interferon alfa-2b, which activates the immune system to fight cancer cells How do I take it?
  • Nadofaragene Firadenovec-vncg - NCI - National Cancer Institute
    This page contains brief information about nadofaragene firadenovec-vncg and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials
  • Adstiladrin Bladder Cancer Treatment | The Urology Group of Virginia
    Adstiladrin Bladder Cancer Treatment Adstiladrin (nadofaragene firadenovec-vncg) is a medicine used to treat adults with a type of bladder cancer called high-risk non-muscle invasive bladder cancer (NMIBC) that has not responded to a treatment called BCG It is for patients who have carcinoma in situ (CIS), with or without small growths called papillary tumors How does Adstiladrin work
  • Ferring Receives Approval from U. S. FDA for Adstiladrin for High-Risk . . .
    Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and safety of Adstiladrin supported by Phase 3 results demonstrating that more than half of patients (51% of CIS ± Ta T1 cohort) achieved a complete response (CR) at three months and of these, 46% continued to remain free of high
  • Package Insert - ADSTILADRIN
    ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (1)





中文字典-英文字典  2005-2009